Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells

被引：45

作者：

Han, Xiaoyun ^{[1
,2
]}

Sheng, Xiugui ^{[1
]}

Jones, Hannah M. ^{[2
]}

Jackson, Amanda L. ^{[2
]}

Kilgore, Joshua ^{[2
]}

Stine, Jessica E. ^{[2
]}

Schointuch, Monica N. ^{[2
]}

Zhou, Chunxiao ^{[2
,3
]}

Bae-Jump, Victoria L. ^{[2
,3
]}

机构：

[1] ShanDong Canc Hosp & Canc Inst, Dept Gynecol Oncol, Jinan 250117, Peoples R China

[2] Univ N Carolina, Div Gynecol Oncol, Chapel Hill, NC 27599 USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷

关键词：

Endometrial Cancer; LDH; Galloflavin; Glycolysis;

D O I：

10.1186/s13045-014-0097-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High rates of aerobic glycolysis represent a key mechanism by which endometrial cancer cells consume glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target whose inhibition has implications for anti-tumor activity in cancer cells. The present study was aimed at evaluating the potential of a novel lactate dehydrogenase (LDH) inhibitor, Galloflavin, as a therapeutic agent for endometrial cancer. Our results revealed that Galloflavin effectively inhibited cell growth in endometrial cancer cell lines and primary cultures of human endometrial cancer through its involvement in multiple signaling pathways that regulate metabolism, cell cycle, apoptosis, cell stress and metastasis.

引用

页数：4

共 8 条

[1] Inhibition of AMPK and Krebs Cycle Gene Expression Drives Metabolic Remodeling of Pten-Deficient Preneoplastic Thyroid Cells
Arciuch, Valeria G. Antico
Russo, Marika A.
Kang, Kristy S.
Di Cristofano, Antonio
[J]. CANCER RESEARCH, 2013, 73 (17) : 5459 - 5472
[2] Billiard J, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-19
[3] Therapeutic targeting of cancer cell metabolism
Dang, Chi V.
Hamaker, Max
Sun, Peng
Le, Anne
Gao, Ping
[J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2011, 89 (03): : 205 - 212
[4] Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways
Farabegoli, F.
Vettraino, M.
Manerba, M.
Fiume, L.
Roberti, M.
Di Stefano, G.
[J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (04) : 729 - 738
[5] Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells
Fiume, Luigi
Vettraino, Marina
Camicelli, Domenica
Arfilli, Valentina
Di Stefano, Giuseppina
Brigotti, Maurizio
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 430 (02) : 466 - 469
[6] Galloflavin (CAS 568-80-9): A Novel Inhibitor of Lactate Dehydrogenase
Manerba, Marcella
Vettraino, Marina
Fiume, Luigi
Di Stefano, Giuseppina
Sartini, Andrea
Giacomini, Elisa
Buonfiglio, Rosa
Roberti, Marinella
Recanatini, Maurizio
[J]. CHEMMEDCHEM, 2012, 7 (02) : 311 - 317
[7] Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis
Nilsson, Lisa M.
Forshell, Tacha Zi Plym
Rimpi, Sara
Kreutzer, Christiane
Pretsch, Walter
Bornkamm, Georg W.
Nilsson, Jonas A.
[J]. PLOS GENETICS, 2012, 8 (03):
[8] Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1
Vettraino, Marina
Manerba, Marcella
Govoni, Marzia
Di Stefano, Giuseppina
[J]. ANTI-CANCER DRUGS, 2013, 24 (08) : 862 - 870

← 1 →